A trial for drug ONX-0801 has shown “very promising” results in with ovarian cancer. A small clinical trial saw tumours shrink in 7 of the 15 women taking part. ONX-0801 mimics the ability of folic acid to latch on to cancer cells. Blocking this action causes damage to the DNA and cell death.
The researchers hope to carry out bigger clinical trials as soon as possible to confirm the effect of ONX-0801 and that it is safe, as well as which women with ovarian cancer it can effectively help to treat.